This Article  • Full text  • PDF  • CME Course for This Article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (220)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Liver/ Biliary Tract/ Pancreatic Diseases  • HIV/AIDS  • Viral Infections  • Pregnancy and Breast Feeding  • Treatment Adherence  • Adherence  • Alert me on articles by topic

2006 Recommendations of the International AIDS Society–USA Panel

Scott M. Hammer, MD; Michael S. Saag, MD; Mauro Schechter, MD, PhD; Julio S. G. Montaner, MD; Robert T. Schooley, MD; Donna M. Jacobsen, BS; Melanie A. Thompson, MD; Charles C. J. Carpenter, MD; Margaret A. Fischl, MD; Brian G. Gazzard, MA, MD; Jose M. Gatell, MD, PhD; Martin S. Hirsch, MD; David A. Katzenstein, MD; Douglas D. Richman, MD; Stefano Vella, MD; Patrick G. Yeni, MD; Paul A. Volberding, MD

JAMA. 2006;296:827-843.

Context  Guidelines for antiretroviral therapy are important for clinicians worldwide given the complexity of the field and the varied clinical situations in which these agents are used. The International AIDS Society–USA panel has updated its recommendations as warranted by new developments in the field.

Objective  To provide physicians and other human immunodeficiency virus (HIV) clinicians with current recommendations for the use of antiretroviral therapy in HIV-infected adults in circumstances for which there is relatively unrestricted access to drugs and monitoring tools. The recommendations are centered on 4 key issues: when to start antiretroviral therapy; what to start; when to change; and what to change. Antiretroviral therapy in special circumstances is also described.

Data Sources and Study Selection  A 16-member noncompensated panel was appointed, based on expertise in HIV research and patient care internationally. Data published or presented at selected scientific conferences from mid 2004 through May 2006 were identified and reviewed by all members of the panel.

Data Extraction and Synthesis  Data that might change previous guidelines were identified and reviewed. New guidelines were drafted by a writing committee and reviewed by the entire panel.

Conclusions  Antiretroviral therapy in adults continues to evolve rapidly, making delivery of state-of-the-art care challenging. Initiation of therapy continues to be recommended in all symptomatic persons and in asymptomatic persons after the CD4 cell count falls below 350/µL and before it declines to 200/µL. A nonnucleoside reverse transcriptase inhibitor or a protease inhibitor boosted with low-dose ritonavir each combined with 2 nucleoside (or nucleotide) reverse transcriptase inhibitors is recommended with choice being based on the individual patient profile. Therapy should be changed when toxicity or intolerance mandate it or when treatment failure is documented. The virologic target for patients with treatment failure is now a plasma HIV-1 RNA level below 50 copies/mL. Adherence to antiretroviral therapy in the short-term and the long-term is crucial for treatment success and must be continually reinforced.

Author Affiliations: Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York (Dr Hammer); Department of Medicine, University of Alabama at Birmingham (Dr Saag); Department of Preventive Medicine, Universidade Federal do Rio de Janeiro, Brazil (Dr Schechter); University of British Columbia, Vancouver (Dr Montaner); Department of Medicine, University of California San Diego, San Diego (Dr Schooley); The International AIDS Society–USA, San Francisco, Calif (Ms Jacobsen); AIDS Research Consortium of Atlanta, Ga (Dr Thompson); Department of Biomedicine, Brown University School of Medicine, Providence, RI (Dr Carpenter); Department of Medicine, University of Miami School of Medicine, Fla (Dr Fischl); Department of HIV Medicine, Chelsea and Westminster Hospital, London, England (Dr Gazzard); Department of Medicine, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain (Dr Gatell); Department of Medicine, Harvard Medical School, Boston, Mass (Dr Hirsch); Departments of Medicine, Stanford University Medical Center, Stanford, Calif (Dr Katzenstein); Departments of Pathology and Medicine, University of California San Diego and San Diego Veterans Affairs Healthcare System, San Diego (Dr Richman); Department of Drug Discovery and Evaluation, Istituto Superiore di Sanità, Rome, Italy (Dr Vella); Department of Infectious Diseases, Hôpital Bichat-Claude Bernard, X. Bichat Medical School, Paris, France (Dr Yeni); Department of Medicine, University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco (Dr Volberding).

RELATED LETTERS

Psychosocial Aspects of HIV Treatment
Kristin Brousseau
JAMA. 2007;297(2):157-158.
EXTRACT | FULL TEXT  

Psychosocial Aspects of HIV Treatment—Reply
Scott M. Hammer and for the International AIDS Society-USA Antiretroviral Therapy Panel
JAMA. 2007;297(2):158.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Impact of Nucleoside Reverse Transcriptase Inhibitors on Mitochondrial DNA and RNA in Human Skeletal Muscle Cells
Saitoh et al.
Antimicrob. Agents Chemother. 2008;52:2825-2830.
ABSTRACT | FULL TEXT  

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel et al.
NEJM 2008;359:339-354.
ABSTRACT | FULL TEXT  

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper et al.
NEJM 2008;359:355-365.
ABSTRACT | FULL TEXT  

HIV Integrase Inhibitors -- Out of the Pipeline and into the Clinic
Havlir
NEJM 2008;359:416-418.
FULL TEXT  

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial
Duvivier et al.
J Antimicrob Chemother 2008;0:dkn278v1-12.
ABSTRACT | FULL TEXT  

Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population
Bhaskaran et al.
JAMA 2008;300:51-59.
ABSTRACT | FULL TEXT  

Evaluation of networks of randomized trials
Salanti et al.
Stat Methods Med Res 2008;17:279-301.
ABSTRACT  

Co-occurrence of Treatment Nonadherence and Continued HIV Transmission Risk Behaviors: Implications for Positive Prevention Interventions
Kalichman
Psychosom. Med. 2008;70:593-597.
ABSTRACT | FULL TEXT  

Class-Sparing Regimens for Initial Treatment of HIV-1 Infection
Riddler et al.
NEJM 2008;358:2095-2106.
ABSTRACT | FULL TEXT  

A Potent HIV Protease Inhibitor, Darunavir, Does Not Inhibit ZMPSTE24 or Lead to an Accumulation of Farnesyl-prelamin A in Cells
Coffinier et al.
J. Biol. Chem. 2008;283:9797-9804.
ABSTRACT | FULL TEXT  

Stavudine plasma concentrations and lipoatrophy
ter Hofstede et al.
J Antimicrob Chemother 2008;61:933-938.
ABSTRACT | FULL TEXT  

Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors
Hachiya et al.
J. Virol. 2008;82:3261-3270.
ABSTRACT | FULL TEXT  

Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle
Proc. Natl. Acad. Sci. USA 2008;105:4832-4837.
 

Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act
Burgoyne and Tan
J Antimicrob Chemother 2008;61:469-473.
ABSTRACT | FULL TEXT  

Efavirenz Accelerates HIV-1 Reverse Transcriptase Ribonuclease H Cleavage, Leading to Diminished Zidovudine Excision
Radzio and Sluis-Cremer
Mol. Pharmacol. 2008;73:601-606.
ABSTRACT | FULL TEXT  

Once-daily dosing of nevirapine in HAART
Clotet
J Antimicrob Chemother 2008;61:13-16.
ABSTRACT | FULL TEXT  

Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3
Sirera et al.
J Antimicrob Chemother 2008;61:191-194.
ABSTRACT | FULL TEXT  

Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients
Llibre et al.
J Antimicrob Chemother 2008;61:206-209.
ABSTRACT | FULL TEXT  

HIV/AIDS: An update
HARRIS and BOLUS
radtech 2008;79:243-252.
ABSTRACT | FULL TEXT  

Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection
Mellgren et al.
Neurology 2007;69:1536-1541.
ABSTRACT | FULL TEXT  

Emergence of HIV-1 Drug Resistance in Previously Untreated Patients Initiating Combination Antiretroviral Treatment: A Comparison of Different Regimen Types
von Wyl et al.
Arch Intern Med 2007;167:1782-1790.
ABSTRACT | FULL TEXT  

Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients
King et al.
Antimicrob. Agents Chemother. 2007;51:3067-3074.
ABSTRACT | FULL TEXT  

Renal disease in an antiretroviral-naive HIV-infected outpatient population in Western Kenya
Wools-Kaloustian et al.
Nephrol Dial Transplant 2007;22:2208-2212.
ABSTRACT | FULL TEXT  

Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice
Molto et al.
J Antimicrob Chemother 2007;60:436-439.
ABSTRACT | FULL TEXT  

Human Immunodeficiency Virus Type 1 Variants Resistant to First- and Second-Version Fusion Inhibitors and Cytopathic in Ex Vivo Human Lymphoid Tissue
Chinnadurai et al.
J. Virol. 2007;81:6563-6572.
ABSTRACT | FULL TEXT  

Both Human Immunodeficiency Virus Cellular DNA Sequencing and Plasma RNA Sequencing Are Useful for Detection of Drug Resistance Mutations in Blood Samples from Antiretroviral-Drug-Naive Patients
Parisi et al.
J. Clin. Microbiol. 2007;45:1783-1788.
ABSTRACT | FULL TEXT  

Prognostic Significance of Immune Subset Measurement in Individuals With AIDS-Associated Kaposi's Sarcoma
Stebbing et al.
JCO 2007;25:2230-2235.
ABSTRACT | FULL TEXT  

Adherence to Nonnucleoside Reverse Transcriptase Inhibitor Based HIV Therapy and Virologic Outcomes
Nachega et al.
ANN INTERN MED 2007;146:564-573.
ABSTRACT | FULL TEXT  

Thailand and the Compulsory Licensing of Efavirenz
Steinbrook
NEJM 2007;356:544-546.
FULL TEXT  

Psychosocial Aspects of HIV Treatment
Brousseau
JAMA 2007;297:157-158.
FULL TEXT  

A Once-Daily Combination Tablet (Atripla) for HIV
Obstet Gynecol 2007;109:195-196.
FULL TEXT  

Getting Smarter -- The Toxicity of Undertreated HIV Infection
Currier and Baden
NEJM 2006;355:2359-2361.
FULL TEXT  

Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques
Kennedy et al.
J. Leukoc. Biol. 2006;80:1175-1182.
ABSTRACT | FULL TEXT  

Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.
Rodriguez et al.
JAMA 2006;296:1498-1506.
ABSTRACT | FULL TEXT  

Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle.
Henry et al.
JAMA 2006;296:1523-1525.
FULL TEXT